Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP707 in chronic central neuropathic pain
NCT06072001Phase 3Recruiting
- Sponsor
- Apurano Pharmaceuticals GmbH
- Start
- Nov 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 3 trial of adezunap in central neuropathic pain (CNP), sponsored by Apurano Pharmaceuticals GmbH. Started Nov 2023; status: recruiting.
02
Drugs
adezunap
03
Conditions
central neuropathic pain (CNP)
Beyond the preview
Go deeper on NCT06072001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06072001.